Two For One

We've got two for one today...two (and almost three) items to examine with just one newsletter. First up, BioCurex is making major progress towards the monetization of their cancer test research. Then we'll take a look at why our Overstock.com pick from a little over a week ago may be off to such a great start.

(Normally we'd hone in on one idea, but I think they're both worth highlighting today. In fact, I think I might start doing multiple - and shorter -takes in all of our newsltters. There's a whole stock market out there to take advantage of, and I want to make sure we're maximizing the help we can offer to our readers.) 
 

	The News Already Predicted By BioCurex's Chart

Well, the recent strength from BioCurex (OTCBB: BOCX) shares all makes sense now. This small cap stock flew from 46 cents to 77 cents over the last six weeks - a 67% move - on rising volume. We speculated that they were going to announce some good progress with the next phase of their cancer detection test, and it looks like we were right. In the same impressive fashion the RECAF test accurately detected the presence of prostate, stomach, colon, cervical, breast, and lung cancer, now a rapid (in-office) RECAF test has been shown to spot ovarian cancer with 88% specificity. 

If at all rings a bell, it's because we've talked about the possibility before. We first mentioned BioCurex was working on a rapid point-of-care test (a device much like a home pregnancy test) back in June. 

The attraction to point-of-care cancer detection is straight-forward...a doctor can screen for cancer in his or her office and get results in a matter of minutes. The alternative is sending samples to a lab, which is more costly, and painfully slow. The best part for BioCurex investors is, there's nothing else like it even on the drawing boards. 

And sure enough, the results of the study are being presented at the International Society for Oncodevelopmental Biology and Medicine (ISOBM) conference, going on now. We blogged that possibility on September 4th. 

It's certainly exciting for the company and its investors, but I believe there's more to the story than the press release explains. The RECAF marker - the technology behind all of BioCurex's research so far - has been shown to work well in multiple formats (blood, serum, tissue samples, and now the rapid test), for multiple cancers (listed above), and do so consistently. How so? It's 88% specific for ovarian cancer when used in a point-of-care test, 90% accurate with prostate cancer is a serum format, 92% accurate for cervical cancer, and so on.

I just see so much potential for RECAF. It's not an expensive technology to utilize (margins could be huge), and it's obviously accurate. And now, it's being successfully used in a practical sense. 

Where's it going next? The ultimate goal is to use the RECAF technology as a way to deliver medicine specifically to cancerous cells. Can that be done? Go back to the success rates and flexibility of what's been done so far...it sure looks it knows how to find cancer cells and avoid non-cancerous ones. It seems to me that's half the battle. 

Here's the best part though...in the meantime, RECAF clearly has potential as a cancer test/marker. Though the drug-delivery version may be years off, the cancer test version of the RECAF technology may be producing revenue before most investors realize it could. Abbott Laboratories (NYSE: ABT) is already on board as a licensee for the blood test. Yet, the deal is non-exclusive - and other licensees could be added to help market other RECAF-based rapid diagnostics. 

The market seems to be responding to the possibility in a highly-positive fashion, pushing BOCX up to new year-to-date highs. And this all happened before the news was released - this stock could go ballistic now that the news is officially publicized. 

The bottom line is, we think BioCurex has made continued progress towards their goal, and it looks like the stock is reflecting that. The risk we run is a 'buy the rumor - sell the news' mentality, but I don't see that happening. Fortunately, we'll know for sure within a matter of minutes. Here's a link to the press release. 
 

	Who Woulda' Thought?

When we suggested Overstock.com (NASDAQ: OSTK) as a trading idea a little more than a week ago, we had no idea this little Internet stock would so quickly take flight. Since the 7th of September, OSTK shares have gained 7.3%. Moreover, this stock seems to still be gaining momentum.

If you didn't take the plunge, don't sweat it - we believe this stock still has a ton of potential from here. We modestly set our target at $30.20, which would be only about a 32.4% gain from our pick price of $22.80. However, having traded in the high $70's in late 2004, we wouldn't be a bit surprised to see OSTK get well past the $30's and closer to the 70's again within a few months, if not weeks. (As such, don't be shocked if we cancel the target later and just let it run.) 

The trick at this point is timing. We've seen six straight days of gains from Overstock, which may even be pushing the limits of the strongest of stocks. Though we expect more of the same here, a pullback to the 20 day moving average (currently at $22.70) might actually be something healthy - and an entry opportunity.

If for some reason that small correction never materializes, then the ball's in your court. Just keep in mind we've got a handful of trading ideas scheduled for the next few weeks, so you're not going to miss out on much if you didn't grab this one (see below).

I also think it's worth mentioning birds of a feather flock together. In other words, Overstock isn't the only Internet stock on a roll. The Merrill Lynch Internet HOLDR's (AMEX: HHH) exchange-traded-fund has also been on the move - since July of 2006. How strong have they been? Try a 32.5% gain over the last twelve months. That didn't create any overnight millionaires, but it sure beats the heck out of the S&P 500's 14.1% during that time.

If Overstock isn't quite your bag but ETF's are, I'd recommend taking a look at HHH. It's easy to own, and last month's pullback to the 200 day line could mean they're still a bargain. 
 

	Don't Forget

Don't forget to keep your eyes peeled for Friday's edition. Tie a string around your finger if you need to. 

We sent a detailed-yet-non-specific newsletter about this company on Sunday explaining the philosophy and basis for our excitement. On Friday though, we're going to start naming names. You may want to keep some capital ear-marked if you like this stock as much as we do. (And if you missed Sunday's newsletter, be sure to click here.) 
 

We Value Your Feedback

Got comments, questions or suggestions? Send 'em on over: Email the Editor If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130

Subscribe

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition.

Click Here or go to http://www.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://www.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://www.smallcapnetwork.com/short_term_alerts.html for Trading Alerts. 

TGR Group, LLC has been paid a fee of $30,000 cash and 1,000,000 shares of newly issued restricted stock by Zupintra Corporation, Inc. for coverage of the Company.

In October of 2003, TGR Group LLC was paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the Company. Under SEC Rule 144, all one million issued restricted shares have been eligible for sale into the public market since October of 2004. In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares and on July 1, 2006 TGR entered into another extended agreement with Biocurex for an additional 100,000 shares of newly issued, restricted stock.)

From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. 

TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed. 

All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. 

The profiles, critiques, and other editorial content of SCN may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein. 

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR. 

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.